The PD‐L1 status plays almost no role in our cohort, as for most of the included patients: renal cell carcinoma, 2nd line urothelial cancer, 2nd line lung cancer treated with nivolumab, and 2nd line head and neck cancer treated with nivolumab—no recommendation of testing the PD‐L1 status has been made by approval status or guidelines. This evidence concerns the gene CD274 and head and neck cancer.